Cyclodextrin-AmB-IL-10 antagonist peptide nanoparticles treat leishmaniasis more effectively than conventional Amphotericin B
This study aimed to create a new nanotherapeutic strategy by combining an interleukin-10 (IL-10) peptide antagonist with amphotericin B (AmB)